Drug-eluting stent having collagen drug carrier chemically treated with genipin
View Patent ↗A method for treating vulnerable plaques of a patient, comprising: providing a biodegradable stent comprising a first supporting zone made of a first biodegradable material, wherein the supporting zone comprises at least a portion of continuous circumference of the stent; and a second therapeutic zone made of a second biodegradable material, wherein the therapeutic zone comprises at least one bioactive agent; delivering the biodegradable stent to the vulnerable plaques; orienting the therapeutic zone at about the luminal surface of the vulnerable plaque; and releasing the at least one bioactive agent for treating the vulnerable plaques.
1. A biodegradable stent for treating vulnerable plaques or atherosclerotic plaques of a patient comprising:
at least two zones, wherein a first supporting zone comprises a first biodegradable material;
a second therapeutic zone comprising a second biodegradable material, wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises lipostabil.
2. A biodegradable stent for treating vulnerable plaques or atherosclerotic plaques of a patient comprising:
at least two zones, wherein a first supporting zone comprises a first biodegradable material;
a second therapeutic zone comprising a second biodegradable material, wherein at least one of the first and the second biodegradable material further comprises a biological material, wherein said biological material is crosslinked with a crosslinking agent or with ultraviolet irradiation; and
wherein the crosslinking agent is genipin, its analog, derivatives, and combination thereof.
3. The stent according to claim 2 , wherein said biological material is selected from the group consisting of collagen, gelatin, elastin, chitosan, N, O, carboxylmethyl chitosan, and mixture thereof.
4. The stent according to claim 2 , wherein at least one of the first and the second biodegradable material is a shape memory polymer.
5. The stent according to claim 2 , wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent.
6. The stent according to claim 2 , wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises lipostabil.
7. The stent according to claim 2 , wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises analgesics/antipyretics.
8. The stent according to claim 2 , wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises ApoA-I Milano or recombinant ApoA-I Milano/phospholipid complexes.
9. The stent according to claim 2 , wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises a growth factor.
10. The stent according to claim 2 , wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises everolimus.
11. The stent according to claim 2 , wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises angiotensin convening enzyme inhibitors.
12. The stent according to claim 2 , wherein at least one of the first and the second biodegradable material comprises at least one bioactive agent and wherein the at least one bioactive agent comprises endothelial progenitor cells.